AstraZeneca (LON:AZN) Stock Jumps 7% - What's Next?

Key Points

• AstraZeneca shares jumped 7% after third-quarter revenue rose 7% to $16.21 billion and profit and EPS exceeded expectations, helping offset generic competition affecting Farxiga.
• Management maintained its fiscal 2026 revenue and core EPS guidance while launching a $1.5 billion savings program to fund pipeline development; oncology momentum, including positive Tagrisso trial results, strengthened the long-term growth outlook.
• Analysts remain broadly positive, with six Buy ratings and one Hold rating producing a consensus “Moderate Buy” and a £153.57 price target, although generic erosion remains a key risk.

Shares of AstraZeneca PLC (LON:AZN - Get Free Report) were up 7% during trading on Friday. The company traded as high as £139.96 and last traded at £139.66. Approximately 40,195,961 shares changed hands during mid-day trading, an increase of 35% from the average daily volume of 29,693,102 shares. The stock had previously closed at £130.52.

Key Stories Impacting AstraZeneca

Here are the key news stories impacting AstraZeneca this week:

• Positive Sentiment: Q3 earnings beat expectations: Revenue rose 7% to $16.21 billion, while quarterly profit increased and EPS more than doubled Wall Street’s estimate. The performance suggests AstraZeneca is successfully managing pressure from generic competition to Farxiga. AstraZeneca Q3 2026 Earnings
• Positive Sentiment: Full-year outlook maintained: Management reaffirmed its fiscal 2026 revenue and core EPS guidance at constant exchange rates, easing concerns that generic erosion or other market pressures could force a downgrade. AstraZeneca Q3 Profit and Guidance
• Positive Sentiment: Pipeline investment and cost savings: AstraZeneca launched a $1.5 billion savings program, with the proceeds intended to support drug development. The CEO also highlighted more than $20 billion in potential from 2027 clinical-trial readouts, strengthening the longer-term growth narrative. AstraZeneca Savings Drive
• Positive Sentiment: Oncology momentum: A Tagrisso combination produced a significant survival benefit in a lung-cancer trial, adding support for AstraZeneca’s key cancer franchise. Tagrisso Lung Cancer Trial
• Positive Sentiment: Analyst support: Jefferies reaffirmed its “buy” rating and set a £175 price target, above recent trading levels, reinforcing bullish sentiment. Jefferies AstraZeneca Recommendation
• Negative Sentiment: Generic competition affecting Farxiga remains a headwind, although stronger cancer-drug sales and the reaffirmed outlook currently appear to be offsetting the risk. AstraZeneca Cancer Drugs and Farxiga

Analyst Ratings Changes

Several research analysts have commented on the company. Citigroup boosted their target price on AstraZeneca from £175 to £178 and gave the stock a "buy" rating in a research note on Tuesday, July 28th. Berenberg Bank reissued a "buy" rating and issued a £175 price target on shares of AstraZeneca in a research note on Wednesday, October 7th. Deutsche Bank Aktiengesellschaft restated a "hold" rating and issued a £117 target price on shares of AstraZeneca in a report on Tuesday, September 29th. Jefferies Financial Group restated a "buy" rating and set a £175 price target on shares of AstraZeneca in a report on Friday. Finally, Royal Bank Of Canada assumed coverage on AstraZeneca in a research report on Tuesday, September 8th. They issued an "outperform" rating and a £145 target price for the company. Six equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of £153.57.

AstraZeneca Trading Up 7.2%

The stock's 50 day simple moving average is £122.69 and its two-hundred day simple moving average is £134.30. The stock has a market capitalization of £217.06 billion, a PE ratio of 20.95, a PEG ratio of 0.86 and a beta of 0.21. The company has a debt-to-equity ratio of 64.10, a current ratio of 0.89 and a quick ratio of 0.59.

Insider Transactions at AstraZeneca

In related news, insider Michel Demare bought 2,500 shares of the business's stock in a transaction on Monday, September 14th. The stock was acquired at an average price of £121.21 per share, for a total transaction of £303,025. Company insiders own 0.15% of the company's stock.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.